Five Prime Shares Triple in Value as Firm Meets All 3 Primary Endpoints in Phase 2 Gastric and GEJ Cancer Trial
Source: Streetwise Reports  (11/11/20)
Five Prime Therapeutics shares traded 250% higher after the firm reported topline data from its Phase 2 FIGHT study of bemarituzumab in combination with chemotherapy demonstrated significant progression-free and overall survival rates in advanced gastric and gastroesophageal junction cancer. More >

Individuals Succeed Using This Digital Therapy—Now It's Moving to Insurers
Source: Matt Badiali for Streetwise Reports  (11/10/20)
Independent financial analyst Matt Badiali profiles a digital therapeutics company that is changing diabetes treatment. More >

Pfizer and BioNTech Announce Extremely Positive Phase 3 COVID-19 Vaccine Trial Data; Production of 1.3 Billion Doses in 2021 Planned
Source: Streetwise Reports  (11/9/20)
Pfizer shares traded 9% higher to a new 52-week high after the company reported that interim data from its Phase 3 COVID-19 vaccine trial with BioNTech showed a 90% success rate in participants without prior evidence of SARS-CoV-2 infection. The company is making plans to produce up to 1.3 billion vaccine doses in 2021. More >

Draganfly Screening Technology Battles Campus, Public Facilities Health Challenges
Source: Knox Henderson for Streetwise Reports  (11/9/20)
Knox Henderson delves into how Draganfly's cutting-edge technology is making it possible for universities and other organizations to operate safely during the pandemic. More >

Glaukos Shares Pressured Higher After Firm Reports 11% Rise in Q3 Revenue
Source: Streetwise Reports  (11/6/20)
Shares of Glaukos Corp. traded 9% higher after the company reported Q3/20 financial results that included an 11% YoY increase in glaucoma and corneal health net sales. More >

U.S. Biotech Developing Cancer Therapeutics Has 'Deep Pipeline'
Source: Streetwise Reports  (11/4/20)
ImmunoGen's broad pipeline that "could support long-term growth" is discussed in an H.C. Wainwright & Co. report. More >

Supernus Pharma Shares Trade Up 21% on 52% Increase in Q3 YoY Revenue
Source: Streetwise Reports  (11/4/20)
Shares of Supernus Pharmaceuticals traded higher after the company reported financial results for Q3/20 that included a 52% increase in total revenues versus the same period in 2019. More >

Inspire Medical's Shareholders Rest Comfortably on Q3 Earnings and Raised FY Outlook
Source: Streetwise Reports  (11/3/20)
Shares of Inspire Medical Systems traded 30% higher and set a new 52-week high after the company reported Q3/20 financial results that included a 72% rise in YoY revenue. More >

Multinational Phase 2b/3 COVID-19 Study Approved to Continue
Source: Streetwise Reports  (11/2/20)
Two doses of Algernon Pharmaceuticals' NP-120, or Ifenprodil, are being tested for safety and efficacy. More >

Acadia Healthcare Shares Rise 20% on Q3 Earnings and Positive Forward Guidance
Source: Streetwise Reports  (10/30/20)
Shares of Acadia Healthcare reached a new 52-week high after the company reported Q3/20 financial results that included a 7.5% YoY increase in revenue at its U.S. health facilities. More >

Biotech Expects Interim Analysis Data from Phase 3 COVID-19 Study by Year-End
Source: Streetwise Reports  (10/28/20)
Revive Therapeutics anticipates that more than 200 patients will complete its Phase 3 clinical trial of Bucillamine in patients with mild-moderate COVID-19 by the end of December 2020 and stated that those results will help identify the best dosage levels for the rest of the trial. More >

Exact Sciences Shares Rise 29% as Firm Announces Q3 Earnings, a Capital Raise and Two Acquisitions
Source: Streetwise Reports  (10/27/20)
Exact Sciences Corp. shares reached a new 52-week high after the maker of cancer screening test Cologuard reported Q3/20 financial results that included a greater than 86% increase in year-over-year revenue. More >

Mirati Therapeutics' Shares Rise 12.5% on Positive Data from Cancer Studies
Source: Streetwise Reports  (10/26/20)
Mirati Therapeutics' shares reached a new 52-week high after the company reported preliminary data for Adagrasib (MRTX849) demonstrated durable anti-tumor activity in its non-small cell lung cancer and colorectal cancer studies. More >

Biopharma White Paper Posits FDA Approval of Biogen's Alzheimer's Drug Likely Next Month
Source: Streetwise Reports  (10/23/20)
ProMIS Neurosciences cites "unequivocally positive data" and encouraging FDA actions with respect to the therapeutic. More >

Align Technology Shares Head Straight Up on 20.9% Q3 Revenue Growth as Firm Celebrates its 9 Millionth Invisalign Patient
Source: Streetwise Reports  (10/22/20)
Shares of Align Technology traded 35% higher and climbed to a new 52-week high after the company reported Q3/20 financial results that included a 20.9% YoY increase in net revenues. More >

Biotech Secures Supplier of Psilocybin, Other Psychedelics
Source: Streetwise Reports  (10/21/20)
Revive Therapeutics will use these products in future studies and clinical trials. More >

Aptinyx Shares Trade 17% Higher on Positive Top-Line Data in Phase 2 PTSD Trial
Source: Streetwise Reports  (10/20/20)
Aptinyx shares set a new 52-week high price after the company reported statistically significant, top-line data from its Phase 2 Study of NYX-783 in patients diagnosed with post-traumatic stress disorder. More >

BioSpecifics Technologies Agrees to $658 Million Buyout Offer from Endo Pharmaceuticals
Source: Streetwise Reports  (10/19/20)
Biospecifics Technologies shares traded 45% higher after the company reported that it agreed to be acquired by Endo Pharmaceuticals for $88.50 per share in an all cash transaction. More >

With Bases Loaded, NervGen Swings for the Fences in Traumatic Brain Injury
Source: Dr. KSS, MD, PhD, for Streetwise Reports  (10/19/20)
Is there anything intracellular sigma peptide, the company's lead agent, can't do, asks Dr. KSS, MD, PhD, editor-in-chief of BioPub.co. More >

Organogenesis Shares Rise 20% on Q3 Net Revenue Growth and FY Guidance
Source: Streetwise Reports  (10/15/20)
Shares of Organogenesis Holdings traded higher after the company reported preliminary Q3/20 financial results demonstrating a 55% increase in year-over-year revenue. More >

Biopharma Announces Pulmonary Fibrosis Trial Now 25% Enrolled
Source: Streetwise Reports  (10/14/20)
Five sites in Australia and New Zealand are participating in this study of Algernon Pharmaceuticals' drug. More >

Life Sciences Firm Lands Record 4 Metric Tons Order for Antibiotic-Free Feedstock
Source: Streetwise Reports  (10/14/20)
Avivagen Inc. reported that it has received a record purchase order for its OxC-betaâ„¢ product from UNAHCO. More >

Phase 3 COVID-19 Study of Firm's Stem Cell Product Exceeds 50% Enrollment
Source: Streetwise Reports  (10/14/20)
The study design and goals and Mesoblast's next steps are reviewed in a Dawson James Securities report. More >

Allscripts Agrees to Sell Its CarePort Health Business for $1.35 Billion
Source: Streetwise Reports  (10/14/20)
Shares of Allscripts Healthcare Solutions traded 30% higher after the company reported it has agreed to sell its CarePort Health business to WellSky Corp. for $1.35 billion. More >

Altimmune Publishes Compelling Preclinical Data for Intranasal COVID-19 Vaccine Candidate
Source: Streetwise Reports  (10/13/20)
Altimmune Inc. shares traded 12% higher after the company published preclinical studies conducted together with the University of Alabama at Birmingham for AdCOVID, its intranasal COVID-19 vaccine candidate. More >